Skip to main content
OpenTrials

Clinical trial condition

Urinary Bladder Neoplasms

Explore clinical trials studying Urinary Bladder Neoplasms. Study availability and eligibility vary by location and protocol.

1,227 public trials 271 recruiting studies
Refine in advanced search Browse all conditions

Urinary Bladder Neoplasms trial results

Recruiting

Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer

NCT07187635

Conditions
Bladder Cancer, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +11 more
Locations
  • Nanchang Second People's Hospital Nanchang, Anhui, China
  • Sun Yat-sen Memorial Hospital of Sun Yat-sen University Guangzhou, Guangdong, China
  • Xingtai People's Hospital Xingtai, Hebei, China
  • The Second Affiliated Hospital of Kunming Medical University Kunming, Yunnan, China
View Trial Details
Recruiting

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

NCT05592626

Conditions
Abdominal Neoplasm, Abdominal Neoplasms, Adenocarcinoma, +91 more
Locations
  • UC Davis Comprehensive Cancer Center Sacramento, California, United States
  • AdventHealth Celebration Celebration, Florida, United States
  • University of Miami Sylvester Comprehensive Cancer Center Miami, Florida, United States
  • The University of Kansas Cancer Center Kansas City, Kansas, United States
View all 19 locations
View Trial Details
Recruiting

A Study of MGC026 in Participants With Advanced Solid Tumors

NCT06242470

Conditions
Adenocarcinoma, Adnexal Diseases, Advanced Cancer, +102 more
Locations
  • The Angeles Clinic and Research Institute Los Angeles, California, United States
  • START Midwest Grand Rapids, Michigan, United States
  • START-New York Long Island Lake Success, New York, United States
  • Providence Cancer Institute Portland, Oregon, United States
View Trial Details
Recruiting

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

NCT04752722

Conditions
Carcinoma, Carcinoma in Situ, Female Urogenital Diseases, +16 more
Locations
  • The University of Alabama at Birmingham Clinical Research Unit (CRU) Birmingham, Alabama, United States
  • Mayo Clinic Scottsdale, Arizona, United States
  • Urological Associates of South Arizona Tucson, Arizona, United States
  • Arkansas Urology Little Rock, Arkansas, United States
View all 102 locations
View Trial Details
Recruiting

IDOV-Immune for Advanced Solid Tumors

NCT06910657

Conditions
Adenocarcinoma, Adnexal Diseases, Adrenal Gland Diseases, +94 more
Locations
  • Washington University School of Medicine St Louis, Missouri, United States
  • MD Anderson Cancer Center Houston, Texas, United States
  • South Texas Accelerated Research Therapeutics San Antonio, Texas, United States
  • Westmead Hospital Westmead, New South Wales, Australia
View Trial Details
Recruiting

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

NCT07000084

Conditions
Carcinoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +15 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Fairbanks Memorial Hospital Fairbanks, Alaska, United States
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
View all 58 locations
View Trial Details

Related conditions